Parkinson Disease (PD)rTMSNCT07310238
Dual-Task Improvement in Parkinson's Via rTMS
A study testing Active Repetitive Transcranial Magnetic Stimulation (rTMS) in people with Parkinson Disease (PD) and Cognition Disorders, run by University of Gaziantep at 1 site in Turkey (Türkiye).
Trial summary
This study aimed to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex on cognitive function and dual-task performance in individuals with Parkinson's disease. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Parkinson Disease (PD), Cognition Disorders, Gait Disorders, Neurologic
- What is being tested?
- Active Repetitive Transcranial Magnetic Stimulation (rTMS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 41 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Nov 2022to 15 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Clinical diagnosis of Parkinson's disease.
- Age 65 years or older.
- Currently receiving dopaminergic therapy.
- Ability to stand independently for at least 30 seconds.
Who cannot join
- Inability to walk for 2 minutes without a walking aid.
- Any contraindication to transcranial magnetic stimulation (e.g., metal implants in the head, history of seizures).
- Musculoskeletal injury or structural abnormality that could affect mobility assessment.
- Presence of another neurological disease.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Repetitive Transcranial Magnetic Stimulation on Dual-task Performance in Patients With Parkinson's Disease
This study aimed to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex on cognitive function and dual-task performance in individuals with Parkinson's disease. Participants completed ten rTMS sessions over two weeks or received sham stimulation. Cognitive status was assessed using the Montreal Cognitive Assessment, and mobility was evaluated through single-task and multiple dual-task Timed Up and Go tests. The study examined whether rTMS could enhance cognitive abilities and improve motor-cognitive performance, which are commonly impaired in Parkinson's disease and contribute to reduced functional independence. Findings indicated that rTMS led to improvements in cognition, single-task mobility, and complex dual-task performance. The intervention was well tolerated, and no adverse events related to the stimulation intensity were reported.
Read the detailed description
Parkinson's disease often leads to declines in cognition, gait performance, and the ability to manage simultaneous cognitive-motor demands. These difficulties contribute to mobility limitations, fall risk, and loss of independence in older adults. This randomized controlled study investigates whether repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex can enhance cognitive function and improve single- and dual-task mobility performance in individuals with Parkinson's disease. Participants complete a two-week intervention consisting of active or sham stimulation. Standardized cognitive and functional mobility assessments are administered before and after the intervention to determine the extent of change associated with rTMS. The study is designed to provide preliminary evidence on whether neuromodulation of an executive-control region can support functional motor-cognitive interactions in this population.
- Being tested
- Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation
- Medical subject headings
- Parkinson Disease, Cognition Disorders, Gait Disorders, Neurologic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active Repetitive Transcranial Magnetic Stimulation (rTMS)Device
Repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex using a figure-8 coil. Stimulation delivered at 5 Hz, 120% of the resting motor threshold, 600 pulses per session, for 10 sessions over two weeks.
Sham Repetitive Transcranial Magnetic StimulationDevice
Sham stimulation performed using the same coil placement, session duration, and procedures as the active rTMS condition, but without magnetic output. Sessions matched in schedule and structure to the active intervention.
| Study group | Role | What they receive |
|---|---|---|
| Active rTMS Group | Experimental | Participants receive repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex at 5 Hz, 120% of the resting motor threshold, for 10 sessions over two weeks. Receives: Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS) |
| Sham Stimulation | Sham comparator | Participants receive sham stimulation using the same coil positioning and session structure as the active rTMS group, but without active magnetic output. Sham sessions match the schedule and duration of the intervention arm. Receives: Device: Sham Repetitive Transcranial Magnetic Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Cognitive Function Measured by the Montreal Cognitive Assessment (MoCA)
The Montreal Cognitive Assessment (MoCA) is a validated screening tool assessing attention, executive function, memory, language, visuospatial abilities, and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive performance. The outcome is defined as the change in total MoCA score from baseline to post-intervention.
Measured: Baseline and after 2 weeks of intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2025
- Study start15 Nov 2022
- Primary completion15 Nov 2025
- Study completion15 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson Disease (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Gaziantep
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Halil Ibrahim ERGEN, University of Gaziantep
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07310238
- Sponsor's protocol ID
- 2022/345
- Acronym
- rTMS
- Status last verified
- Dec 2025
- First submitted
- 16 Dec 2025
- Last updated
- 30 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because the study involves a small sample size from a single clinical center, and the available data contain identifiable health information that cannot be fully anonymized for public release. No data-sharing infrastructure or repository has been established for this project.
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Repetitive Transcranial Magnetic Stimulation on Dual-task Performance in Patients With Parkinson's Disease
- ClinicalTrials.gov ID
- NCT07310238
- Acronym / sponsor ID
- rTMS / 2022/345
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 41 participants (actual)
- Lead sponsor
- University of GaziantepUniversity, hospital or other
- Study start
- 15 Nov 2022 (actual)
- Primary completion
- 15 Nov 2025 (actual)
- Study completion
- 15 Nov 2025 (actual)
- First posted
- 30 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex on cognitive function and dual-task performance in individuals with Parkinson's disease. Participants completed ten rTMS sessions over two weeks or received sham stimulation. Cognitive status was assessed using the Montreal Cognitive Assessment, and mobility was evaluated through single-task and multiple dual-task Timed Up and Go tests. The study examined whether rTMS could enhance cognitive abilities and improve motor-cognitive performance, which are commonly impaired in Parkinson's disease and contribute to reduced functional independence. Findings indicated that rTMS led to improvements in cognition, single-task mobility, and complex dual-task performance. The intervention was well tolerated, and no adverse events related to the stimulation intensity were reported.
Detailed description
Parkinson's disease often leads to declines in cognition, gait performance, and the ability to manage simultaneous cognitive-motor demands. These difficulties contribute to mobility limitations, fall risk, and loss of independence in older adults. This randomized controlled study investigates whether repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex can enhance cognitive function and improve single- and dual-task mobility performance in individuals with Parkinson's disease. Participants complete a two-week intervention consisting of active or sham stimulation. Standardized cognitive and functional mobility assessments are administered before and after the intervention to determine the extent of change associated with rTMS. The study is designed to provide preliminary evidence on whether neuromodulation of an executive-control region can support functional motor-cognitive interactions in this population.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active rTMS Group | Experimental | Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS)Participants receive repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex at 5 Hz, 120% of the resting motor threshold, for 10 sessions over two weeks. |
| Sham Stimulation | Sham comparator | Device: Sham Repetitive Transcranial Magnetic StimulationParticipants receive sham stimulation using the same coil positioning and session structure as the active rTMS group, but without active magnetic output. Sham sessions match the schedule and duration of the intervention arm. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- Clinical diagnosis of Parkinson's disease.
- Age 65 years or older.
- Currently receiving dopaminergic therapy.
- Ability to stand independently for at least 30 seconds.
Key exclusion criteria (4 listed)
- Inability to walk for 2 minutes without a walking aid.
- Any contraindication to transcranial magnetic stimulation (e.g., metal implants in the head, history of seizures).
- Musculoskeletal injury or structural abnormality that could affect mobility assessment.
- Presence of another neurological disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active Repetitive Transcranial Magnetic Stimulation (rTMS)Repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex using a figure-8 coil. Stimulation delivered at 5 Hz, 120% of the resting motor threshold, 600 pulses per session, for 10 sessions over two weeks. | Device | Active rTMS Group |
| Sham Repetitive Transcranial Magnetic StimulationSham stimulation performed using the same coil placement, session duration, and procedures as the active rTMS condition, but without magnetic output. Sessions matched in schedule and structure to the active intervention. | Device | Sham Stimulation |
Primary outcome
Change in Cognitive Function Measured by the Montreal Cognitive Assessment (MoCA)
Time frame: Baseline and after 2 weeks of intervention
The Montreal Cognitive Assessment (MoCA) is a validated screening tool assessing attention, executive function, memory, language, visuospatial abilities, and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive performance. The outcome is defined as the change in total MoCA score from baseline to post-intervention.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2025.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because the study involves a small sample size from a single clinical center, and the available data contain identifiable health information that cannot be fully anonymized for public release. No data-sharing infrastructure or repository has been established for this project.
Related trials for Parkinson Disease (PD)
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Recruiting
Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease
Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
Parkinson&Amp;#39;s Disease
RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
RecruitingPhase 2/3
A Study of Buntanetap in Participants With PD
Parkinson's Disease (PD), Deep Brain Stimulation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active Repetitive Transcranial Magnetic Stimulation (rTMS) in people with Parkinson Disease (PD) and Cognition Disorders, run by University of Gaziantep at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Cognitive Function Measured by the Montreal Cognitive Assessment (MoCA) (time frame: Baseline and after 2 weeks of intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2025.